Third Pole Therapeutics said it has successfully completed an early feasibility study of its portable inhaled nitric oxide (iNO) delivery device, eNOfit, allowing the company to move to larger trials for pulmonary hypertension (PH) associated with interstitial lung disease.
WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — Third Pole Therapeutics, a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and infectious diseases, announced today the successful completion of an early feasibility study (EFS) performed under an Investigational Device Exemption granted by the FDA. This study evaluated eNOfit™, a miniaturized, portable inhaled nitric oxide (iNO) generator …
– Data from Study Anticipated in Q1 2024 WALTHAM, Mass., December 11, 2023 (GLOBE NEWSWIRE) – Third Pole Therapeutics, Inc., Third Pole Therapeutics, a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and infectious diseases, today announced that the first patient has been dosed in an early feasibility study (EFS) performed under an Investigational Device Exemption granted …
Funding will support the final development phase prior to planned 2023 FDA submission of the company’s “breakthrough” designated eNOcare™ hospital device Waltham, MA –December 14, 2022 – Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. Bill Athenson, CEO of Third Pole, stated, “We are …
The severity of COVID-19 respiratory failure in some patients has taken the medical community by surprise. And in response, that community has been trying just about anything that seems reasonable in an effort to improve outcomes — and in some cases as last-resort measures to save lives.
Medical researchers are testing whether inhaled nitric oxide could help treat patients with the coronavirus.
Researchers at Massachusetts General Hospital (MGH) are studying whether inhaling a gas called nitric oxide can help treat patients with COVID-19, or even prevent people from getting the disease.
Doctors from around the world are seeing if the gas that gave us the ‘little blue pill’ will also help treat the novel coronavirus as it continues to spread.
Scientists in Massachusetts, Italy, and elsewhere are experimenting with a familiar medical treatment for the new problem of covid-19. They’ve begun clinical trials meant to find out whether inhaled nitric oxide can save people who are severely sick from the new coronavirus. This treatment might even be used preventatively to keep health care workers infection-free.
Never before, scientists say, have so many of the world’s researchers focused so urgently on a single topic. Nearly all other research has ground to a halt.